NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES



Canada House Wellness Group Provides Bi-Weekly Update on Status of Management Cease Trade Order.

Toronto September 27, 2017. Canada House Wellness Group Inc. (CSE: CHV) ("Canada House" or the "Company") wishes to provide a bi-weekly status update further to the management cease trade order ("MCTO") issued by the Ontario Securities Commission in respect of the Company's securities under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). The MCTO only prohibits the interim Chief Executive Officer and the Chief Financial Officer from trading in or purchasing the securities of the Company until two business days after all filings are brought up to date. The Company also has imposed a blackout on trading by all other directors, officers and insiders.

The MCTO was issued in respect of the Company's inability to file its audited financial statements for the year ended April 30, 2017 and the management's discussion and analysis and related Chief Executive Officer and Chief Financial Officer certificates for this period (collectively, the "**Required Filings**") before the August 28, 2017 filing deadline.

The Company continues to work diligently to effect the Required Filings and has made significant progress in respect thereof. The Company expects to effect the Required Filings on or before October 16, 2017. The filing of the Required Filings has been delayed beyond the end of September while the Company responds to questions and comments received from the Company's auditors in the course of the auditor's file reviews process.

The Company anticipates effecting the filing of its interim unaudited financial statements for the quarter ended July 31, 2017 and related management's discussion and analysis and Chief Executive Officer and Chief Financial Officer certificates at the same time that it effects the Required Filings.

The Company has agreed to terms of settlement in respect of the legal proceedings initiated against a former director and former officer of the Company related to the ownership of Ananda Clinics Inc. ("Ananda") and access to records of Ananda (the "Settlement"). The documentation of the Settlement as a formal judgment of the Court will allow the Company to complete and file the Required Filings. The Company anticipates the formal judgment of the Court will be issued shortly.

The MCTO will be in effect until two business days after all filings are up to date.

Until such time as all filings are up to date, the Company will continue to provide biweekly status reports to its shareholders and in so doing, comply with the provisions of the alternative information guidelines set out in Sections 9 and 10 of NP 12-203.

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit http://www.canadahouse.ca. or www.sedar.com

For further information, please contact:

Boom Capital Markets Steve Low 647-620-5101 steve@boomcapitalmarkets.com

Canada House Wellness Group, Inc. Gerry Goldberg (416) 460-3000 mailto:ggoldberg@abbamedix.com

Cautionary Statement Regarding Forward Looking Information. Certain statements within this news release pertaining to the Company constitute "forward looking statements", within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward looking statements". Such "forward looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company's public disclosure record. The Company assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.